IDEAYA Biosciences, Inc. (IDYA)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Unrealized gains (losses) on marketable securities | -64 | 773 | 5,252 | |
| Research and development | 74,226 | 70,886 | 57,152 | |
| General and administrative | 14,580 | 13,503 | 9,741 | |
| Total operating expenses | 88,806 | 84,389 | 66,893 | |
| Loss from operations | -88,806 | -84,389 | -66,893 | |
| Interest income and other income, net | 11,315 | 12,211 | 15,072 | |
| Net loss | -77,491 | -72,178 | -51,821 | |
| Comprehensive loss | -77,555 | -71,405 | -46,569 | |
| Earnings per share, basic | -0.88 | -0.82 | -0.6 | |
| Earnings per share, diluted | -0.88 | -0.82 | -0.6 | |
| Weighted average number of shares outstanding, basic | 88,472,197 | 88,356,335 | 86,188,510 | |
| Weighted average number of shares outstanding, diluted | 88,472,197 | 88,356,335 | 86,188,510 | |